Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Settings
2.2. Ethical Clearance
2.3. Animals and Housing
2.4. Experimental Design
2.5. Measurement of Health Outcomes Associated with NAFLD
2.5.1. Body Mass
2.5.2. Terminal Procedures
2.5.3. Sample Processing for Histology
2.5.4. Liver Histology and Scoring for Non-Alcoholic Fatty Liver Disease
2.5.5. Total Liver Lipid Content Determination
3. Statistical Analysis
4. Results
4.1. Hepatosomatic Index (Relative %BM) and Percentage (%) Lipid Content of Liver of Male and Female Rats
- Hepatosomatic index of male rats
- b.
- Hepatosomatic index of female rats
- c.
- Hepatic lipid content in male rats
- d.
- Hepatic lipid content in female rats
4.2. Liver Histopathology
- Microvesicular steatosis in male rats
- b.
- Microvesicular steatosis in female rats
- c.
- Macrovesicular steatosis in male rats
- d.
- Macrovesicular steatosis in female rats
- e.
- Hypertrophy in male rats
- f.
- Hypertrophy in female rats
- g.
- Inflammation in male rats
- h.
- Inflammation in female rats
- i.
- Area fraction of collagen in male rats
- j.
- Area fraction of collagen in female rats
5. Discussion
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gerges, S.H.; Wahdan, S.A.; Elsherbiny, D.A.; El-Demerdash, E. Non-Alcoholic Fatty Liver Disease: An Overview of Risk Factors, Pathophysiological Mechanisms, Diagnostic Procedures, and Therapeutic Interventions. Life Sci. 2021, 271, 1–17. [Google Scholar] [CrossRef]
- Sherif, A.Z. The rise in the prevalence of nonalcoholic fatty liver disease and hepatocellular carcinoma. In Nonalcoholic Fatty Liver Disease—An Update; IntechOpen: London, UK, 2019; pp. 1–36. [Google Scholar] [CrossRef] [Green Version]
- Idalsoaga, F.; Kulkarni, A.V.; Mousa, O.Y.; Arrese, M.; Arab, J.P. Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front. Med. 2020, 7, 448. [Google Scholar] [CrossRef]
- Kasper, P.; Martin, A.; Lang, S.; Kütting, F.; Goeser, T.; Demir, M.; Steffen, H.M. NAFLD and Cardiovascular Diseases: A Clinical Review. Clin. Res. Cardiol. 2021, 110, 921–937. [Google Scholar] [CrossRef]
- Younossi, Z.M. Non-Alcoholic Fatty Liver Disease–A Global Public Health Perspective. J. Hepatol. 2019, 70, 531–544. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.Y. Genetic and Epigenetic Variants Influencing the Development of Nonalcoholic Fatty Liver Disease. World J. Gastroenterol. 2012, 18, 6546. [Google Scholar] [CrossRef]
- Roeb, E.; Weiskirchen, R. Fructose and Non-Alcoholic Steatohepatitis. Front. Pharmacol. 2021, 12, 47. [Google Scholar] [CrossRef]
- Taskinen, M.R.; Packard, C.J.; Borén, J. Dietary Fructose and the Metabolic Syndrome. Nutrients 2019, 11, 1987. [Google Scholar] [CrossRef] [Green Version]
- Geidl-Flueck, B.; Hochuli, M.; Németh, Á.; Eberl, A.; Derron, N.; Köfeler, H.C.; Tappy, L.; Berneis, K.; Spinas, G.A.; Gerber, P.A. Fructose- and Sucrose- but Not Glucose-Sweetened Beverages Promote Hepatic de Novo Lipogenesis: A Randomized Controlled Trial. J. Hepatol. 2021, 75, 46–54. [Google Scholar] [CrossRef]
- Muhammad, N.; Lembede, B.W.; Erlwanger, K.H. Neonatal Zingerone Protects against the Development of High-Fructose Diet-Induced Metabolic Syndrome in Adult Sprague-Dawley Rats. J. Dev. Orig. Health Dis. 2021, 12, 671–679. [Google Scholar] [CrossRef]
- Day, C.P.; James, O.F.W. Steatohepatitis: A Tale of Two “Hits”? Gastroenterology 1998, 114, 842–845. [Google Scholar] [CrossRef]
- Schmidt, N.H.; Svendsen, P.; Albarrán-Juárez, J.; Moestrup, S.K.; Bentzon, J.F. High-Fructose Feeding Does Not Induce Steatosis or Non-Alcoholic Fatty Liver Disease in Pigs. Sci. Rep. 2021, 11, 1–10. [Google Scholar] [CrossRef]
- DiStefano, J.K. Fructose-Mediated Effects on Gene Expression and Epigenetic Mechanisms Associated with NAFLD Pathogenesis. Cell. Mol. Life Sci. 2020, 77, 2079–2090. [Google Scholar] [CrossRef]
- Jacob, J.S.; Ahmed, A.; Cholankeril, G. The Impact of Alteration in Gut Microbiome in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Curr. Opin. Infect. Dis. 2021, 34, 477–482. [Google Scholar] [CrossRef]
- Francque, S.; Vonghia, L. Pharmacological treatment for non-alcoholic fatty liver disease. In Advances in Therapy; Springer: Berlin/Heidelberg, Germany, 2019; pp. 1052–1074. [Google Scholar] [CrossRef] [Green Version]
- Pennisi, G.; Celsa, C.; Spatola, F.; Dallio, M.; Federico, A.; Petta, S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int. J. Environ. Res. Public Health 2019, 16, 4334. [Google Scholar] [CrossRef] [Green Version]
- Xiao, J.; Zhai, H.; Yao, Y.; Wang, C.; Jiang, W.; Zhang, C.; Simard, A.R.; Zhang, R.; Hao, J. Chrysin Attenuates Experimental Autoimmune Neuritis by Suppressing Immuno-Inflammatory Responses. Neuroscience 2014, 262, 156–164. [Google Scholar] [CrossRef]
- Rehman, M.U.; Ali, N.; Rashid, S.; Jain, T.; Nafees, S.; Tahir, M.; Khan, A.Q.; Lateef, A.; Khan, R.; Hamiza, O.O.; et al. Alleviation of Hepatic Injury by Chrysin in Cisplatin Administered Rats: Probable Role of Oxidative and Inflammatory Markers. Pharmacol. Rep. 2014, 66, 1050–1059. [Google Scholar] [CrossRef]
- Mani, R.; Natesan, V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. In Phytochemistry; Elsevier: Amsterdam, The Netherlands, 2018; pp. 187–196. [Google Scholar] [CrossRef]
- Neal-Kluever, A.; Fisher, J.; Grylack, L.; Kakiuchi-Kiyota, S.; Halpern, W. Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. Drug Metab. Dispos. 2019, 47, 296–313. [Google Scholar] [CrossRef]
- Vanier, M.T.; Holm, M.; ÖHman, R.; Svennerholm, L. Developmental Profiles of Gangliosides in Human and Rat Brain. J. Neurochem. 1971, 18, 581–592. [Google Scholar] [CrossRef]
- Romijn, H.J.; Hofman, M.A.; Gramsbergen, A. At What Age Is the Developing Cerebral Cortex of the Rat Comparable to That of the Full-Term Newborn Human Baby? Early Hum. Dev. 1991, 26, 61–67. [Google Scholar] [CrossRef]
- Satyanarayana, K.; Sravanthi, K.; Shaker, I.; Ponnulakshmi, R.; Selvaraj, J. Role of Chrysin on Expression of Insulin Signaling Molecules. J. Ayurveda Integr. Med. 2015, 6, 248. [Google Scholar] [CrossRef] [Green Version]
- Liang, W.; Menke, A.L.; Driessen, A.; Koek, G.H.; Lindeman, J.H.; Stoop, R.; Havekes, L.M.; Kleemann, R.; van den Hoek, A.M. Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology. PLoS ONE 2014, 9, 1–17. [Google Scholar] [CrossRef] [Green Version]
- Ibrahim, K.G.; Chivandi, E.; Nkomozepi, P.; Matumba, M.G.; Mukwevho, E.; Erlwanger, K.H. The Long-Term Protective Effects of Neonatal Administration of Curcumin against Nonalcoholic Steatohepatitis in High-Fructose-Fed Adolescent Rats. Physiol. Rep. 2019, 7, 1–17. [Google Scholar] [CrossRef]
- Srigley, C.T.; Mossoba, M.M. Dietetics and Clinical Nutrition Commons, Health and Medical Administration Commons. 2017, p. 7. Available online: http://digitalcommons.unl.edu/usfda/7 (accessed on 22 May 2022).
- Pai, S.A.; Munshi, R.P.; Panchal, F.H.; Gaur, I.S.; Juvekar, A.R. Chrysin Ameliorates Nonalcoholic Fatty Liver Disease in Rats. Naunyn. Schmiedebergs. Arch. Pharmacol. 2019, 392, 1617–1628. [Google Scholar] [CrossRef]
- Gritti, E.S.; Barbot, B. Developmental Plasticity. Encycl. Personal. Individ. Differ. 2019, 1–3. [Google Scholar] [CrossRef]
- Valentini, F.; Rocchi, G.; Vespasiani-Gentilucci, U.; Guarino, M.P.L.; Altomare, A.; Carotti, S. The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period. Cells 2022, 11, 562. [Google Scholar] [CrossRef]
- Campisano, S.; La Colla, A.; Echarte, S.M.; Chisari, A.N. Interplay between Early-Life Malnutrition, Epigenetic Modulation of the Immune Function and Liver Diseases. Nutr. Res. Rev. 2019, 32, 128–145. [Google Scholar] [CrossRef]
- Castillo-Leon, E.; Cioffi, C.E.; Vos, M.B. Perspectives on Youth-Onset Nonalcoholic Fatty Liver Disease. Endocrinol. Diabetes Metab. 2020, 3, e00184. [Google Scholar] [CrossRef]
- Ji, C.; Dai, Y.; Jiang, W.; Liu, J.; Hou, M.; Wang, J.; Burén, J.; Li, X. Postnatal Overfeeding Promotes Early Onset and Exaggeration of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Disordered Hepatic Lipid Metabolism in Rats. J. Nutr. Biochem. 2014, 25, 1108–1116. [Google Scholar] [CrossRef]
- Pandit, D.N.; Gupta, M.L. Heapto-Somatic Index, Gonado-Somatic Index and Condition Factor of Anabas Testudineus as Bio-Monitoring Tools of Nickel and Chromium Toxicity. Int. J. Innov. Eng. Technol. 2019, 12, 25–28. [Google Scholar] [CrossRef]
- Mamikutty, N.; Thent, Z.C.; Haji Suhaimi, F. Fructose-Drinking Water Induced Nonalcoholic Fatty Liver Disease and Ultrastructural Alteration of Hepatocyte Mitochondria in Male Wistar Rat. Biomed. Res. Int. 2015, 2015, 895961. [Google Scholar] [CrossRef] [Green Version]
- Dupas, J.; Feray, A.; Goanvec, C.; Guernec, A.; Samson, N.; Bougaran, P.; Guerrero, F.; Mansourati, J. Metabolic Syndrome and Hypertension Resulting from Fructose Enriched Diet in Wistar Rats. Biomed. Res. Int. 2017, 2017, 2494067. [Google Scholar] [CrossRef]
- Koch, L.K.; Yeh, M.M. Nonalcoholic Fatty Liver Disease (NAFLD): Diagnosis, Pitfalls, and Staging. Ann. Diagn. Pathol. 2018, 37, 83–90. [Google Scholar] [CrossRef]
- Narayanan, J.M.; Jesudoss, V.A.S. Hepatoprotective Potential of Zingerone against Nonalcoholic Fatty Liver Disease in Rats Fed with Fructose-Enriched Diet. Gen. Physiol. Biophys. 2016, 35, 185–194. [Google Scholar] [CrossRef]
- Jensen, T.; Abdelmalek, M.F.; Sullivan, S.; Nadeau, K.J.; Green, M.; Roncal, C.; Nakagawa, T.; Kuwabara, M.; Sato, Y.; Kang, D.-H.; et al. Fructose and Sugar: A Major Mediator of Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2018, 68, 1063–1075. [Google Scholar] [CrossRef] [Green Version]
- Karsdal, M.A.; Daniels, S.J.; Holm Nielsen, S.; Bager, C.; Rasmussen, D.G.K.; Loomba, R.; Surabattula, R.; Villesen, I.F.; Luo, Y.; Shevell, D.; et al. Collagen Biology and Non-Invasive Biomarkers of Liver Fibrosis. Liver Int. 2020, 40, 736–750. [Google Scholar] [CrossRef] [Green Version]
- Kanuri, G.; Bergheim, I. In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD). Int. J. Mol. Sci. 2013, 14, 11963–11980. [Google Scholar] [CrossRef] [Green Version]
- Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism 2016, 65, 1038–1048. [Google Scholar] [CrossRef]
- Cusi, K. Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clin. Liver Dis. 2009, 13, 545–563. [Google Scholar] [CrossRef]
- Cusi, K. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology 2012, 142, 711–725. [Google Scholar] [CrossRef]
- Kirpich, I.A.; Marsano, L.S.; McClain, C.J. Gut-Liver Axis, Nutrition, and Non Alcoholic Fatty Liver Disease. Clin. Biochem. 2015, 48, 923. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ajah, A.A.; Lembede, B.W.; Nkomozepi, P.; Erlwanger, K.H.; Nyakudya, T.T. Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats. Life 2022, 12, 790. https://doi.org/10.3390/life12060790
Ajah AA, Lembede BW, Nkomozepi P, Erlwanger KH, Nyakudya TT. Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats. Life. 2022; 12(6):790. https://doi.org/10.3390/life12060790
Chicago/Turabian StyleAjah, Austin A., Busisani W. Lembede, Pilani Nkomozepi, Kennedy H. Erlwanger, and Trevor T. Nyakudya. 2022. "Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats" Life 12, no. 6: 790. https://doi.org/10.3390/life12060790